Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
Trial details
- Registry ID
- NCT05288855
- Phase
- Phase 3
The FDA approved Voclosporin on 22 Jan 2021.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Voclosporin in Adolescent and Pediatric Subjects With Lupus NephritisNCT05288855 | AUPH | Phase 3 | Terminated | 2025-07-03Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2021-01-22Day | Voclosporin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA213716", "applicant_as_listed_by_fda": "AURINIA", "brand_names": ["LUPKYNIS"], "active_ingredients": ["VOCLOSPORIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20210122", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |